Business
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago.
About this update from Genprex, Inc.
[{"type":"text","content":"Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells","length":96,"tagName":"p","attribs":{}},{"type":"text","content":"AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, at the 2025 American Diabetes Association (ADA) 85th Scientific Session in Chicago.","length":509,"tagName":"p"},{"type":"image","alt":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","displaySize":"","headline":null,"caption":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xA37qCr88_2_J9WjJLKhZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1798169/Genprex_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are proud of the research presented at the ADA conference, which demonstrates that alpha cells in animal models of T1D have undergone transdifferentiation to beta-like cells after being transduced with GPX-002. In addition, the beta-like cells were still providing improved control of glucose levels after three months," said Ryan Confer, President and Chief Executive Officer at Genprex. "We are very excited to continue evaluating GPX-002 as we further optimize how to control anti-viral immunity and move toward human clinical trials."","length":562,"tagName":"p"},{"type":"text","content":"The oral presentation details for the Genprex-supported abs...